摘要
目的：比较左西替利嗪和孟鲁司特钠对中-重度持续性儿童变应性鼻炎（ AR）患者症状评分和生活质量评分的改善作用,探讨儿童AR的个体化药物治疗方案。方法将157例年龄6~14岁的中-重度持续性AR患儿,随机分为左西替利嗪（LEVO）组77例与孟鲁司特（MONT）组80例。 LEVO组每晚口服左西替利嗪片5mg,MONT组每晚口服孟鲁司特钠片5mg。应用鼻炎症状评分体系进行评价,评分越低症状越轻。结果治疗2周,两组症状总评分差异无统计学意义（F=1．157,P〉0．05）,但均较基线差异有统计学意义（F=0．404和0．485,P〈0．01）,流涕症状LEVO组改善优于MONT组（F=0．744,P〈0．05）,鼻塞症状MONT组改善优于LEVO组（F=0．819,P=0．013〈0．05）；治疗4周,两组症状总评分差异无统计学意义（F=1．240,P〉0．05）,但较基线（F=0．158和0．203,P均〈0．01）和2周前差异有统计学意（F=0．391和0．419,P〈0．01）,鼻塞症状MONT组改善极优于LEVO组（F=0．304,P=0．001〈0．01）。结论对于鼻塞症状明显的患儿,可以选择孟鲁司特钠作为初始治疗药物；对于流涕症状明显的患儿,可以选择盐酸左西替利嗪作为初始治疗药物。
Objective To compare the effects of Levocetirizine and Montelukast on persistent allergic rhinitis （ AR ） in children and explore individualized therapy for child AR. Methods 157 children（6~14 years）with moderate to severe persistent AR were evenly randomized into two groups treated by Levocetirizine（ LEVO, 77 patients） or Montelukast（ MONT, 80 patients） . The effects of two groups were compared in terms of rhinitis symptoms. Results Treatment after two weeks, the total symptom score between the two groups was not statistically significant（F=1. 157, P〉 0. 05）compared with the baseline, but there was a significant difference（F=0. 404 and 0. 485, P〈0. 01）, runny nose symptoms improved in LEVO group than in MONT group （F=0. 744, P〈0. 05）, MONT group improved nasal symptoms than LEVO group（F=0. 819, P=0. 013〈0. 05）;4 weeks after treatment, total symptom score between the two groups was not statistically significant（F=1. 240, P〉 0. 05）, but lower than the baseline（F=0. 158 and 0. 203, P〈0. 01）, and two weeks later（F=0. 391 and 0. 419, P 〈0. 01）, there was a significant difference in improvement in nasal symptoms MONT group which very superior than LEVO group（F=0. 304, P=0. 001〈0. 01）. Conclusion For the nasal symptoms in children, we can choose Montelukast as initial therapy; for the runny nose symptoms in children, we can select the Levocetirizine as initial therapy.
出处
《四川医学》
CAS
2015年第9期1299-1301,共3页
Sichuan Medical Journal
